BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 18488884)

  • 1. Vocal aging and adductor spasmodic dysphonia: response to botulinum toxin injection.
    Cannito MP; Kahane JC; Chorna L
    Clin Interv Aging; 2008; 3(1):131-51. PubMed ID: 18488884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interarytenoid muscle botox injection for treatment of adductor spasmodic dysphonia with vocal tremor.
    Kendall KA; Leonard RJ
    J Voice; 2011 Jan; 25(1):114-9. PubMed ID: 20137891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum toxin treatment of false vocal folds in adductor spasmodic dysphonia: Functional outcomes.
    Simpson CB; Lee CT; Hatcher JL; Michalek J
    Laryngoscope; 2016 Jan; 126(1):118-21. PubMed ID: 26467807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum toxin management of adductor spasmodic dysphonia after failed recurrent laryngeal nerve section.
    Sulica L; Blitzer A; Brin MF; Stewart CF
    Ann Otol Rhinol Laryngol; 2003 Jun; 112(6):499-505. PubMed ID: 12834116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botox treatment in adductor spasmodic dysphonia: a meta-analysis.
    Boutsen F; Cannito MP; Taylor M; Bender B
    J Speech Lang Hear Res; 2002 Jun; 45(3):469-81. PubMed ID: 12069000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of Onabotulinum Toxin A Treatment for Adductor Spasmodic Dysphonia and Laryngeal Tremor.
    Patel PN; Kabagambe EK; Starkweather JC; Keller M; Gamsarian V; Lee J; Kulkarni V; Garrett CG; Francis DO
    JAMA Otolaryngol Head Neck Surg; 2018 Apr; 144(4):293-299. PubMed ID: 29423509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of ventricular dysphonia with botulinum toxin.
    Kendall KA; Leonard RJ
    Laryngoscope; 1997 Jul; 107(7):948-53. PubMed ID: 9217137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients.
    Blitzer A; Brin MF; Stewart CF
    Laryngoscope; 1998 Oct; 108(10):1435-41. PubMed ID: 9778279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulcus vocalis in spasmodic dysphonia-A retrospective study.
    Nerurkar NK; Agrawal D; Joshi D
    Am J Otolaryngol; 2021; 42(3):102940. PubMed ID: 33545449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective review of dosing trends in botulinum toxin injections for the treatment of adductor spasmodic dysphonia in a long-term cohort.
    French G; Bosch JD; Randall DR
    J Otolaryngol Head Neck Surg; 2020 Jan; 49(1):4. PubMed ID: 31937363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liquid-type Botulinum Toxin Type A in Adductor Spasmodic Dysphonia: A Prospective Pilot Study.
    Cha W; Jang JY; Wang SG; Kang JH; Jo MG
    J Voice; 2017 May; 31(3):378.e19-378.e24. PubMed ID: 27520509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adductor spasmodic dysphonia: Botulinum toxin a injections or laser thyroarytenoid myoneurectomy? A comparison from the patient perspective.
    Schuering JHC; Heijnen BJ; Sjögren EV; Langeveld APM
    Laryngoscope; 2020 Mar; 130(3):741-746. PubMed ID: 31169922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laryngeal Botulinum Toxin Injection for Vocal Tremor: Utility of Concurrent Strap Muscle Injection.
    Nelson RC; Silva Merea V; Tierney WS; Milstein C; Benninger MS; Bryson PC
    Laryngoscope; 2019 Jun; 129(6):1433-1437. PubMed ID: 30588631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternating Unilateral Versus Bilateral Injections of Botulinum Toxin for the Treatment of Adductor Spasmodic Dysphonia.
    Lee SJ; Kang MS; Choi HS; Lim JY
    Otolaryngol Head Neck Surg; 2021 Apr; 164(4):815-820. PubMed ID: 32957836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of botulinum toxin on pathophysiology in spasmodic dysphonia.
    Bielamowicz S; Ludlow CL
    Ann Otol Rhinol Laryngol; 2000 Feb; 109(2):194-203. PubMed ID: 10685573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal effects of botulinum toxin injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia.
    Hogikyan ND; Wodchis WP; Spak C; Kileny PR
    J Voice; 2001 Dec; 15(4):576-86. PubMed ID: 11792036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia.
    Troung DD; Rontal M; Rolnick M; Aronson AE; Mistura K
    Laryngoscope; 1991 Jun; 101(6 Pt 1):630-4. PubMed ID: 2041443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of botulinum toxin in the treatment of adductor spasmodic dysphonia.
    Whurr R; Lorch M; Fontana H; Brookes G; Lees A; Marsden CD
    J Neurol Neurosurg Psychiatry; 1993 May; 56(5):526-30. PubMed ID: 8505645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perceptual analyses of spasmodic dysphonia before and after treatment.
    Cannito MP; Woodson GE; Murry T; Bender B
    Arch Otolaryngol Head Neck Surg; 2004 Dec; 130(12):1393-9. PubMed ID: 15611398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of symptoms for spasmodic dysphonia and vocal tremor: a comparison of expert and nonexpert judges.
    Barkmeier JM; Case JL; Ludlow CL
    J Commun Disord; 2001; 34(1-2):21-37. PubMed ID: 11322567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.